WBR0880: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Physiology |SubCategory=Hematology |MainCategory=Physiology |SubCategory=Hematology |MainCategory=Ph...")
 
No edit summary
Line 20: Line 20:
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Hematology
|SubCategory=Hematology
|Prompt=A 56 year old man is admitted to the hospital for severe angina, dyspnea, and diaphoresis. His initial labs are significant for elevated troponins. The man undergoes emergent PCI and is discharged home several days later on dual antiplatelet therapy consisting of aspirin and clopidogrel. Which of the following steps in primary hemostasis is inhibited by aspirin and clopidogrel respectively?  
|Prompt=A 56 year old man is admitted to the hospital for severe angina, dyspnea, and diaphoresis. His initial labs are significant for elevated troponins. The man undergoes emergent PCI and is discharged home several days later on dual antiplatelet therapy consisting of aspirin and clopidogrel. Which of the following steps in primary hemostasis is inhibited by aspirin and clopidogrel respectively?
|AnswerA=vWF binding GpIb, ADP release  
|Explanation=Dual antiplatelet therapy is the standard of care in patients undergoing PCI. Aspirin in combination with clopidogrel is one of the possible combinations used. Aspirin is an irreversible inhibitor of both COX1 and COX2 which has analgesic, anti-inflammatory, and antiplatelet (mostly at low doses) characteristics. Aspirin decreases thromboxane A2 production leading to a decrease in platelet aggregation. Clopidogrel on the other hand is an ADP receptor blocker that inhibits ADP mediated expression of GpIIb/IIIa on the surface of platelets required to bind fibrinogen.
 
 
Learning objective: Both aspirin and clopidogrel play a role in decreasing platelet aggregation, aspirin via decreasing thromboxane A2 and clopidogrel via blocking ADP receptors and decresing GpIIbIIIa expression.
 
 
Reference:<br>
Savi P, Nurden P, Nurden AT, Levy-toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9(3-4):251-5.<br>
Vane J, Botting R. The mechanism of action of aspirin. Thrombosis Research. 2003;110(5-6):255-258.
|AnswerA=vWF binding GpIb, ADP release
|AnswerAExp=Neither of these mechanisms is inhibited by aspirin or clopidogrel.
|AnswerB=vWF binding collagen, GpIIbIIIa expression
|AnswerB=vWF binding collagen, GpIIbIIIa expression
|AnswerBExp=Although clopidogrel inhibits GpIIbIIIa expression by blocking ADP receptors, aspirin doesn't inhibit vWF binding to collagen.
|AnswerC=Thromboxane A2 release, GpIIbIIIa binding fibrinogen
|AnswerC=Thromboxane A2 release, GpIIbIIIa binding fibrinogen
|AnswerCExp=Although aspirin blocks thromboxane A2 release, clopidogrel does not inhibit GpIIbIIIa binding fibrinogen. C
|AnswerD=Thromboxane A2 release, GpIIbIIIa expression
|AnswerD=Thromboxane A2 release, GpIIbIIIa expression
|AnswerDExp=Aspirin inhibits thromboxane A2 release while clopidogrel blocks GpIIbIIIa expression.
|AnswerE=Thromboxane A2 release, ADP release
|AnswerE=Thromboxane A2 release, ADP release
|AnswerEExp=Although aspirin blocks thromboxane A2 release, clopidogrel does not inhibit ADP release. Clopidogrel is responsible for blocking the ADP receptors that mediate GpIIbIIIa expression.
|RightAnswer=D
|RightAnswer=D
|WBRKeyword=clopidogrel, aspirin, primary hemostasis
|Approved=No
|Approved=No
}}
}}

Revision as of 01:02, 11 November 2013

 
Author [[PageAuthor::Rim Halaby, M.D. [1]]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Physiology
Sub Category SubCategory::Hematology
Prompt [[Prompt::A 56 year old man is admitted to the hospital for severe angina, dyspnea, and diaphoresis. His initial labs are significant for elevated troponins. The man undergoes emergent PCI and is discharged home several days later on dual antiplatelet therapy consisting of aspirin and clopidogrel. Which of the following steps in primary hemostasis is inhibited by aspirin and clopidogrel respectively?]]
Answer A AnswerA::vWF binding GpIb, ADP release
Answer A Explanation AnswerAExp::Neither of these mechanisms is inhibited by aspirin or clopidogrel.
Answer B AnswerB::vWF binding collagen, GpIIbIIIa expression
Answer B Explanation AnswerBExp::Although clopidogrel inhibits GpIIbIIIa expression by blocking ADP receptors, aspirin doesn't inhibit vWF binding to collagen.
Answer C AnswerC::Thromboxane A2 release, GpIIbIIIa binding fibrinogen
Answer C Explanation AnswerCExp::Although aspirin blocks thromboxane A2 release, clopidogrel does not inhibit GpIIbIIIa binding fibrinogen. C
Answer D AnswerD::Thromboxane A2 release, GpIIbIIIa expression
Answer D Explanation AnswerDExp::Aspirin inhibits thromboxane A2 release while clopidogrel blocks GpIIbIIIa expression.
Answer E AnswerE::Thromboxane A2 release, ADP release
Answer E Explanation AnswerEExp::Although aspirin blocks thromboxane A2 release, clopidogrel does not inhibit ADP release. Clopidogrel is responsible for blocking the ADP receptors that mediate GpIIbIIIa expression.
Right Answer RightAnswer::D
Explanation [[Explanation::Dual antiplatelet therapy is the standard of care in patients undergoing PCI. Aspirin in combination with clopidogrel is one of the possible combinations used. Aspirin is an irreversible inhibitor of both COX1 and COX2 which has analgesic, anti-inflammatory, and antiplatelet (mostly at low doses) characteristics. Aspirin decreases thromboxane A2 production leading to a decrease in platelet aggregation. Clopidogrel on the other hand is an ADP receptor blocker that inhibits ADP mediated expression of GpIIb/IIIa on the surface of platelets required to bind fibrinogen.


Learning objective: Both aspirin and clopidogrel play a role in decreasing platelet aggregation, aspirin via decreasing thromboxane A2 and clopidogrel via blocking ADP receptors and decresing GpIIbIIIa expression.


Reference:
Savi P, Nurden P, Nurden AT, Levy-toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9(3-4):251-5.
Vane J, Botting R. The mechanism of action of aspirin. Thrombosis Research. 2003;110(5-6):255-258.
Educational Objective:
References: ]]

Approved Approved::No
Keyword WBRKeyword::clopidogrel, WBRKeyword::aspirin, WBRKeyword::primary hemostasis
Linked Question Linked::
Order in Linked Questions LinkedOrder::